|Last Price$89.40||Day Change (%)-0.02%|
|Open Price$89.37||Day Change ($)-0.02|
|Day Range89.32–89.46||52-Week Range46.56–89.46|
As of Thu 7/30/2015 5:47:00 PM | USD
Pfizer Boosts Its Earnings Outlook -- Update
Pfizer Boosts Its Earnings Outlook
Research and Markets: Biosimilars Market by Product (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin) - Global Forecasts to 2020
Most of Morningstar's top Medalists are shining in a pack of broad returns.
Research and Markets: Haemophilus Influenzae Infections - API Insights 2015-2016
Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
Welcome to Hospira's First Quarter 2014 Conference Call. All lines have been placed on listen-only mode to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer period.
Despite the sector looking slightly overvalued, we still see stocks with attractive valuations across the different industries.